Population-based Atrial Fibrillation Screening in Individuals With NT-proBNP Above Median in the Tromsø Study
Recruiting
N/A
Interventional Study
Atrial Fibrillation (AF)
Stroke
NT-pro-BNP
Cognitive Function and Well-Being
Heart Failure
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 40 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Screening
- Participants needed
- 4,000 (estimated)
- Sponsor
- University Hospital of North Norway · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The aim is to investigate whether screening with long-term ECG monitoring in individuals with elevated NT-proBNP leads to a lower incidence of ischeamic stroke and death from vascular causes. The project is a sub-study within the 8th wave of the population based Tromsø Study. Information on previous diseases, medication use, and risk factors is collected through questionnaires, blood samples, and …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age ≥40 years
* NT-proBNP\> median level
* Informed consent for participation
Exclusion Criteria:
* History of AF (self-reported)
* Use of anticoagulation therapy
* Pacemaker/CRT device
* No available smart phone
Contacts